Barclays has revised its price target for Johnson & Johnson (JNJ, Financial), lowering it slightly from $166 to $165. Despite this adjustment, the firm continues to rate the shares as Equal Weight following the company's first-quarter results.
Johnson & Johnson's quarterly performance showcased robust outcomes in its Pharma division. However, this was counterbalanced by slower growth in the MedTech segment. Analysts attribute this slower growth primarily to unique, non-recurring issues and challenges from the previous year.
Moreover, Johnson & Johnson has retained its financial outlook for 2025, even while navigating through the effects of deal dilution and tariff impacts. Barclays recognized these factors in its evaluation, which influenced the minor adjustment in the stock’s price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Johnson & Johnson (JNJ, Financial) is $170.72 with a high estimate of $185.00 and a low estimate of $150.00. The average target implies an upside of 10.92% from the current price of $153.91. More detailed estimate data can be found on the Johnson & Johnson (JNJ) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Johnson & Johnson's (JNJ, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Johnson & Johnson (JNJ, Financial) in one year is $187.82, suggesting a upside of 22.03% from the current price of $153.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Johnson & Johnson (JNJ) Summary page.
